参考文献/References:
[1] SIEPER J,PODDUBNYY D.Axial spondyloarthritis[J].Lancet,2017,390(10089):73-84.
[2] 刘倩,马亮,岳德波,等.强直性脊柱炎患者HLA-B27基因分型及临床特征分析[J].中日友好医院学报,2020,34(5):271-273.
[3] 徐胜前,黄烽.强直性脊柱炎的关节外损害及治疗[J].中华内科杂志,2018,57(3):171-174.
[4] BREWERTON D A,HART F D,NICHOLLS A,et al.Ankylosing spondylitis and HL-A 27[J].Lancet,1973,1(7809):904-907.
[5] RAMOS M,LPEZ DE CASTRO J A.HLA-B27 and the pathogenesis of spondyloarthritis[J].Tissue Antigens,2002,60(3):191-205.
[6] BROWN M A,KENNEDY L G,MACGREGOR A J,et al.Susceptibility to ankylosing spondylitis in twins:the role of genes,HLA,and the environment[J].Arthritis Rheum,1997,40(10):1823-1828.
[7] CHUNG H Y,MACHADO P,VAN DER HEIJDE D,et al.HLA-B27 positive patients differ from HLA-B27 negative patients in clinical presentation and imaging:results from the DESIR cohort of patients with recent onset axial spondyloarthritis[J].Ann Rheum Dis,2011,70(11):1930-1936.
[8] BROWN M A,LAVAL S H,BROPHY S,et al.Recurrence risk modelling of the genetic susceptibility to ankylosing spondylitis[J].Ann Rheum Dis,2000,59(11):883-886.
[9] 高乐女,吴红,游苘霞,等.7829例疑似强直性脊柱炎患者HLA-B27抗原阳性率及分型研究[J].第三军医大学学报,2020,42(12):1220-1224.
[10] 孙国华,李艳莲,肖晓光.应用PCR-SSP方法检测HLA-B27亚型及其临床意义[J].大连医科大学学报,2006,28(5):410-413.
[11] ELLINGHAUS D,JOSTINS L,SPAIN S L,et al.Analysis of five chronic inflammatory diseases identifies 27 new associations and highlights disease-specific patterns at shared loci[J].Nat Genet,2016,48(5):510-518.
[12] PEDERSEN S J,MAKSYMOWYCH W P.The pathogenesis of ankylosing spondylitis:an update[J].Curr Rheumatol Rep,2019,21(10):58.
[13] PALADINI F,FIORILLO M T,TEDESCHI V,et al.Ankylosing spondylitis:a trade off of HLA-B27,ERAP,and pathogen interconnections?focus on Sardinia[J].Front Immunol,2019,10:35.
[14] YORIFUJI H,ARASE N,KOHYAMA M,et al.Transport of cellular misfolded proteins to the cell surface by HLA-B27 free heavy chain[J].Biochem Biophys Res Commun,2019,511(4):862-868.
[15] SHELDON P.Specific cell-mediated responses to bacterial antigens and clinical correlations in reactive arthritis,Reiter’s syndrome and ankylosing spondylitis[J].Immunol Rev,1985,86:5-25.
[16] LIU B,YANG L,CUI Z,et al.Anti-TNF-α therapy alters the gut microbiota in proteoglycan-induced ankylosing spondylitis in mice[J].Microbiologyopen,2019,8(12):e927.
[17] YANG L,LIU B,ZHENG J,et al.Rifaximin alters intestinal microbiota and prevents progression of ankylosing spondy-litis in mice[J].Front Cell Infect Microbiol,2019,9:44.
[18] ZIEBOLZ D,DOUGLAS D,DOUGLAS D,et al.Periodontal condition is associated with disease duration and motoric disabilities in patients with ankylosing spondylitis:results of a cross-sectional study[J].Rheumatol Int,2018,38(5):855-863.
[19] BARALIAKOS X,BAERLECKEN N,WITTE T,et al.High prevalence of anti-CD74 antibodies specific for the HLA class II-associated invariant chain peptide(CLIP)in patients with axial spondyloarthritis[J].Ann Rheum Dis,2014,73(6):1079-1082.
[20] SIEPER J,PODDUBNYY D,MIOSSEC P.The IL-23-IL-17 pathway as a therapeutic target in axial spondyloarthritis[J].Nat Rev Rheumatol,2019,15(12):747-757.
[21] FURUE K,ITO T,FURUE M.Differential efficacy of bio-logic treatments targeting the TNF-α/IL-23/IL-17 axis in psoriasis and psoriatic arthritis[J].Cytokine,2018,111:182-188.
[22] 方乐,董少梅,张祖雯,等.强直性脊柱炎患者外周血免疫细胞Th17水平与预后的相关性分析[J].临床医学研究与实践,2021,6(1):11-14.
[23] JIN L,WEISMAN M,ZHANG G,et al.Lack of association of matrix metalloproteinase 3(MMP3)genotypes with ankylosing spondylitis susceptibility and severity[J].Rheumatology(Oxford),2005,44(1):55-60.
[24] JARLBORG M,COURVOISIER D S,LAMACCHIA C,et al.Serum calprotectin:a promising biomarker in rheumatoid arthritis and axial spondyloarthritis[J].Arthritis Res Ther,2020,22(1):105.
[25] SYRBE U,CALLHOFF J,CONRAD K,et al.Serum adipokine levels in patients with ankylosing spondylitis and their relationship to clinical parameters and radiographic spinal progression[J].Arthritis Rheumatol,2015,67(3):678-685.
[26] TORRES L,KLINGBERG E,NURKKALA M,et al.Hepatocyte growth factor is a potential biomarker for osteoproliferation and osteoporosis in ankylosing spondylitis[J].Osteoporos Int,2019,30(2):441-449.
[27] BLEIL J,MAIER R,HEMPFING A,et al.Granulation tissue eroding the subchondral bone also promotes new bone formation in ankylosing spondylitis[J].Arthritis Rheumatol,2016,68(10):2456-2465.
[28] VAN DER LINDEN S,VALKENBURG H A,CATS A.Evaluation of diagnostic criteria for ankylosing spondylitis.A proposal for modification of the New York criteria[J].Arthritis Rheum,1984,27(4):361-368.
[29] RUDWALEIT M,VAN DER HEIJDE D,LANDEWé R,et al.The development of assessment of spondyloarthritis international society classification criteria for axial spondyloarthritis(part II):validation and final selection[J].Ann Rheum Dis,2009,68(6):777-783.
[30] RUDWALEIT M,VAN DER HEIJDE D,LANDEWé R,et al.The assessment of spondyloarthritis international so-ciety classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general[J].Ann Rheum Dis,2011,70(1):25-31.
[31] 孔祥权,张权.MRI和X线在强直性脊柱炎骶髂关节病变的诊断价值分析[J].现代医用影像学,2020,29(2):264-266.
[32] 中华医学会风湿病学分会.强直性脊柱炎诊治指南(草案)[J].中华风湿病学杂志,2003,7(10):641-644.
[33] PODDUBNYY D,RUDWALEIT M,HAIBEL H,et al.Rates and predictors of radiographic sacroiliitis progression over 2 years in patients with axial spondyloarthritis[J].Ann Rheum Dis,2011,70(8):1369-1374.
[34] VAN DEN BERG R,LENCZNER G,FEYDY A,et al.Agreement between clinical practice and trained central reading in reading of sacroiliac joints on plain pelvic radiographs Results from the DESIR cohort[J].Arthritis Rheumatol,2014,66(9):2403-2411.
[35] 王艳,田荣华.CT与磁共振成像在早期强直性脊柱炎骶髂关节病变中的诊断价值对比[J].基层医学论坛,2019,23(1):83-84.
[36] 范晓云,李志军.强直性脊柱炎的诊断与治疗[J].中华全科医学,2020,18(8):1256-1257.
[37] 徐海东,郑淑凤.探讨X线、CT和MRI在早期强直性脊柱炎骶髂关节病变诊断中的应用价值[J].影像研究与医学应用,2020,4(23):234-236.
[38] 张奉贤,王朋.X线、CT与MRI联合诊断早期强直性脊柱炎骶髂关节病变的诊断符合情况分析[J].影像研究与医学应用,2020,4(19):117-118.
[39] WEBER U,BARALIAKOS X.Imaging in axial spondyloarthritis:Changing concepts and thresholds[J].Best Pract Res Clin Rheumatol,2018,32(3):342-356.
[40] BRAUN J,BARALIAKOS X,BUEHRING B,et al.Imaging of axial spondyloarthritis.New aspects and differential diagnoses[J].Clin Exp Rheumatol,2018,36 Suppl 114(5):35-42.
[41] DE WINTER J,DE HOOGE M,VAN DE SANDE M,et al.Magnetic resonance imaging of the sacroiliac joints indi-cating sacroiliitis according to the assessment of spondyloarthritis international society definition in healthy individuals,runners,and women with postpartum back pain[J].Arthritis Rheumatol,2018,70(7):1042-1048.
[42] 张函光.MRI在早期AS骶髂关节病变诊断中应用价值研究[J].中国医学创新,2020,17(31):69-72.
[43] 林馥纯,王豫平,袁胜超,等.超声在活动期强直性脊柱炎患者骶髂关节评估中初步应用[J].现代医用影像学,2019,28(8):1715-1718.
[44] REN J,ZHU J,LI D,et al.The value of contrast-enhanced ultrasonography to detect the sacroiliac joint for predicting relapse after discontinuation of anti-tumor necrosis factor therapy in patients with ankylosing spondylitis[J].Quant Imaging Med Surg,2019,9(6):1110-1117.
[45] NAREDO E,BATLLE-GUALDA E,GARCíA-VIVAR M L,et al.Power Doppler ultrasonography assessment of entheses in spondyloarthropathies:response to therapy of entheseal abnormalities[J].J Rheumatol,2010,37(10):2110-2117.
[46] MOLINA COLLADA J,MACíA-VILLA C,PLASENCIA C,et al.Doppler enthesitis:a potential useful outcome in the assessment of axial spondyloarthritis and psoriatic arthritis[J].Clin Rheumatol,2021,40(5):2013-2020.
[47] SIEBUHR A S,HUSAKOVá M,FOREJTOVá S,et al.Metabolites of C-reactive protein and vimentin are associated with disease activity of axial spondyloarthritis[J].Clin Exp Rheumatol,2019,37(3):358-366.
[48] 刘勤,陶金辉,马艳,等.血清抗链球菌溶血素O效价与强直性脊柱炎病情及不同药物治疗影响的关联性研究[J].中华疾病控制杂志,2018,22(10):1055-1058.
[49] 陆锡平,王科,张庆祥,等.强直性脊柱炎患者检测HLA-B27、ASO及免疫球蛋白表达的临床意义[J].分子诊断与治疗杂志,2020,12(9):1256-1259.
[50] PéCOURNEAU V,DEGBOé Y,BARNETCHE T,et al.Effectiveness of exercise programs in ankylosing spondylitis:a meta-analysis of randomized controlled trials[J].Arch Phys Med Rehabil,2018,99(2):383-389.
[51] 张琳,张佳蕾,郭郁,等.基于Cobb角测量法分析五禽戏调节脊柱曲度及柔韧性研究[J].辽宁中医药大学学报,2018,20(4):94-97.
[52] XIE Y,GUO F,LU Y,et al.A 12-week Baduanjin Qigong exercise improves symptoms of ankylosing spondylitis:A randomized controlled trial[J].Complement Ther Clin Pract,2019,36:113-119.
[53] 曲昆,马丛,刘晓光,等.太极强脊操干预强直性脊柱炎40例效果评价[J].北京中医药,2020,39(6):629-632.
[54] Z? A,CANTISTA P.The role of land and aquatic exercise in ankylosing spondylitis:a systematic review[J].Rheumatol Int,2017,37(12):1979-1990.
[55] 凌春生,曾密,王冠,等.督脉灸联合腹针治疗强直性脊柱炎临床观察[J].广西中医药大学学报,2020,23(3):1-4.
[56] 郭大江,王彩悦,尹智龙,等.督灸疗法治疗肾虚督寒型强直性脊柱炎45例[J].中国中医药现代远程教育,2021,19(8):120-121.
[57] 马明璐,陈发祥,陈翠翠.中医针灸综合治疗强直性脊柱炎的临床效果[J].中外医学研究,2021,19(14):173-175.
[58] 范瑞华.中医针灸综合治疗强直性脊柱炎的临床效果[J].深圳中西医结合杂志,2019,29(3):55-57.
[59] 王伟,刘雪梅.延续护理心理干预方式对强直性脊柱炎患者抑郁和焦虑状态的影响[J].中国健康心理学杂志,2018,26(4):555-558
[60] 赵翠芬,晁少荣,董春燕,等.微信平台用于强直性脊柱炎早期患者功能锻炼指导[J].护理学杂志,2016,31(13):89-91.
[61] SONG I H,PODDUBNYY D A,RUDWALEIT M,et al.Benefits and risks of ankylosing spondylitis treatment with nonsteroidal antiinflammatory drugs[J].Arthritis Rheum,2008,58(4):929-938.
[62] SIEPER J,KLOPSCH T,RICHTER M,et al.Comparison of two different dosages of celecoxib with diclofenac for the treatment of active ankylosing spondylitis:results of a 12-week randomised,double-blind,controlled study[J].Ann Rheum Dis,2008,67(3):323-329.
[63] HAROON N N,PATERSON J M,LI P,et al.Patients with ankylosing spondylitis have increased cardiovascular and cerebrovascular mortality:a population-based study[J].Ann Intern Med,2015,163(6):409-416.
[64] Coxib and Traditional NSAID Trialists’(CNT)Collaboration.Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs:meta-analyses of in-dividual participant data from randomised trials[J].Lancet,2013,382(9894):769-779.
[65] FAN M,LIU J,ZHAO B,et al.Indirect comparison of NSAIDs for ankylosing spondylitis:Network meta-analysis of randomized,double-blinded,controlled trials[J].Exp Ther Med,2020,19(4):3031-3041.
[66] ZHANG J R,PANG D D,DAI S M.Non-steroidal anti-inflammatory drugs are unlikely to inhibit radiographic progression of ankylosing spondylitis:a systematic review[J].Front Med(Lausanne),2019,6:214.
[67] 曾沛英,蔡章洪,周耿民,等.传统抗风湿药物对强直性脊柱炎的疗效:十年临床观察[J].中华风湿病学杂志,2020,24(3):159-164.
[68] WARD M M,DEODHAR A,GENSLER L S,et al.2019 update of the American College of rheumatology/spondylitis association of America/spondyloarthritis research and treatment network recommendations for the treatment of anky-losing spondylitis and nonradiographic axial spondyloarth-ritis[J].Arthritis Rheumatol,2019,71(10):1599-1613.
[69] KHANNA SHARMA S,KADIYALA V,NAIDU G,et al.A randomized controlled trial to study the efficacy of sulfasalazine for axial disease in ankylosing spondylitis[J].Int J Rheum Dis,2018,21(1):308-314.
[70] HAIBEL H,BRANDT H C,SONG I H,et al.No efficacy of subcutaneous methotrexate in active ankylosing spondylitis:a 16-week open-label trial[J].Ann Rheum Dis,2007,66(3):419-421.
[71] YANG Z,ZHAO W,LIU W,et al.Efficacy evaluation of methotrexate in the treatment of ankylosing spondylitis using meta-analysis[J].Int J Clin Pharmacol Ther,2014,52(5):346-351.
[72] WANG C,LI W.Effects of etanercept and infliximab on bone metabolism indexes in patients with ankylosing spondylitis[J].Exp Ther Med,2020,19(1):585-590.
[73] MAKSYMOWYCH W P,STRAND V,NASH P,et al.Comparative effectiveness of secukinumab and adalimumab in ankylosing spondylitis as assessed by matching-adjusted indirect comparison[J].Eur J Rheumatol,2018,5(4):216-223.
[74] SAYED ABDULLA J,SHI J,ROY B S,et al.Patients with ankylosing spondylitis treatment by golimumab:a systematic review and meta-analysis[J].Eur Spine J,2020,29(8):1813-1822.
[75] DEODHAR A,GENSLER L S,KAY J,et al.A fifty-two-week,randomized,placebo-controlled trial of certolizumab pegol in nonradiographic axial spondyloarthritis[J].Arthritis Rheumatol,2019,71(7):1101-1111.
[76] HAIBEL H,HELDMANN F,BRAUN J,et al.Long-term efficacy of adalimumab after drug withdrawal and retreatment in patients with active non-radiographically evident axial spondyloarthritis who experience a flare[J].Arthritis Rheum,2013,65(8):2211-2213.
[77] YATES M,HAMILTON L E,ELENDER F,et al.Is etanercept 25 mg once weekly as effective as 50 mg at maintaining response in patients with ankylosing spondylitis?A randomized control trial[J].J Rheumatol,2015,42(7):1177-1185.
[78] BRAUN J,BARALIAKOS X,HERMANN K G,et al.The effect of two golimumab doses on radiographic progression in ankylosing spondylitis:results through 4 years of the GO-RAISE trial[J].Ann Rheum Dis,2014,73(6):1107-1113.
[79] VAN DER HEIJDE D,RAMIRO S,LANDEWé R,et al.2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis[J].Ann Rheum Dis,2017,76(6):978-991.
[80] DUNDAR U,?VIK H,DEMIRDAL U S,et al.Use of rituximab to treat a patient with coexistence of rheumatoid arthritis and ankylosing spondylitis:18 months follow-up[J].Int J Rheum Dis,2018,21(10):1869-1872.
[81] MCGONAGLE D G,MCINNES I B,KIRKHAM B W,et al.The role of IL-17A in axial spondyloarthritis and psoriatic arthritis:recent advances and controversies[J].Ann Rheum Dis,2019,78(9):1167-1178.
[82] BLAIR H A.Secukinumab:a review in ankylosing spondylitis[J].Drugs,2019,79(4):433-443.
[83] VAN DER HEIJDE D,CHENG-CHUNG WEI J,DOUGADOS M,et al.Ixekizumab,an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs(COAST-V):16 week results of a phase 3 randomised,double-blind,active-controlled and placebo-controlled trial[J].Lancet,2018,392(10163):2441-2451.
[84] DEODHAR A,PODDUBNYY D,PACHECO-TENA C,et al.Efficacy and safety of ixekizumab in the treatment of radiographic axial spondyloarthritis:sixteen-week results from a phase III randomized,double-blind,placebo-controlled trial in patients with prior inadequate response to or intolerance of tumor necrosis factor inhibitors[J].Arthritis Rheumatol,2019,71(4):599-611.
[85] DEODHAR A,GENSLER L S,SIEPER J,et al.Three multicenter,randomized,double-blind,placebo-controlled studies evaluating the efficacy and safety of ustekinumab in axial spondyloarthritis[J].Arthritis Rheumatol,2019,71(2):258-270.
[86] VAN DER HEIJDE D,DEODHAR A,WEI J C,et al.Tofacitinib in patients with ankylosing spondylitis:a phase II,16-week,randomised,placebo-controlled,dose-ranging study[J].Ann Rheum Dis,2017,76(8):1340-1347.
[87] VAN DER HEIJDE D,SONG I H,PANGAN A L,et al.Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis(SELECT-AXIS 1):a multicentre,randomised,double-blind,placebo-controlled,phase 2/3 trial[J].Lancet,2019,394(10214):2108-2117.
[88] VAN DER HEIJDE D,BARALIAKOS X,GENSLER L S,et al.Efficacy and safety of filgotinib,a selective Janus kinase 1 inhibitor,in patients with active ankylosing spondylitis(TORTUGA):results from a randomised,placebo-controlled,phase 2 trial[J].Lancet,2018,392(10162):2378-2387.
[89] 曾沛英,庄成乐,何家莉,等.糖皮质激素在强直性脊柱炎治疗中的临床观察[J].山西医药杂志,2019,48(3):288-291.
[90] SIU S,HARAOUI B,BISSONNETTE R,et al.Meta-analysis of tumor necrosis factor inhibitors and glucocorticoids on bone density in rheumatoid arthritis and ankylosing spondylitis trials[J].Arthritis Care Res(Hoboken),2015,67(6):754-764.
[91] 焦树德.大(尢+娄)(强直性脊柱炎)病因病机及辨证论治探讨(上)[J].江苏中医药,2003,24(1):1-3.
[92] 黃育敏,张敬灿.麻黄附子细辛汤合泽泻汤加味联合督脉灸治疗风寒湿痹型强直性脊柱炎的疗效观察[J].中国中医药科技,2021,28(3):432-433.
[93] 向鹏飞,姚璐莎,王莘智.王莘智从脾胃论治强直性脊柱炎经验[J].中医临床研究,2021,13(13):91-93.
[94] 方妍妍,刘健,万磊,等.323例强直性脊柱炎患者健脾化湿益肾通络方药应用的队列研究[J].中国中西医结合杂志,2019,39(5):553-556.
[95] 程悦,纪伟.雷公藤及其相关制剂治疗强直性脊柱炎的临床研究进展[J].现代医学,2020,48(7):920-924.
[96] 梁志刚.雷公藤多甙治疗强直性脊柱炎的临床有效性研究[J].中国实用医药,2017,12(1):136-137.
[97] 沈括,王小蕊,华青措,等.雷公藤多苷片联合依那西普治疗强直性脊柱炎患者的临床研究[J].中国临床药理学杂志,2020,36(19):2996-2999.
[98] 李宇,史天陆,张永煌,等.雷公藤多苷片治疗强直性脊柱炎疗效及安全性的系统评价[J].中国医院用药评价与分析,2016,16(12):1680-1685.
[99] LIN D,CHARALAMBOUS A,HANNA S A.Bilateral total hip arthroplasty in ankylosing spondylitis:a systematic review[J].EFORT Open Rev,2019,4(7):476-481.
[100]WANG T,ZHENG G,WANG Y,et al.Comparison of 2 surgeries in correction of severe kyphotic deformity caused by ankylosing spondylitis:vertebral column decancellation and pedicle subtraction osteotomy[J].World Neurosurg,2019,127:e972-e978.
[101]ZHANG X,ZHANG Z,WANG J,et al.Vertebral column decancellation:a new spinal osteotomy technique for correcting rigid thoracolumbar kyphosis in patients with anky-losing spondylitis[J].Bone Joint J,2016,98-B(5):672-678.